Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.30 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.30 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9498067 | 0.78 | TAAR1 (0.61) | SMN1; SMN2TAAR1FAAH | |
| SCHEMBL9498059 | 0.78 | TAAR1 (0.61) | SMN1; SMN2TAAR1FAAH | |
| SCHEMBL1094445 | 0.77 | SRC (0.42) | SMN1; SMN2TAAR1 | |
| SCHEMBL1095564 | 0.74 | TAAR1 (0.40) | TAAR1KDR | |
| SCHEMBL30443362 | 0.73 | TAAR1 (0.52) | SMN1; SMN2TAAR1ADRA2AADRA2BADRA2C | |
| SCHEMBL16260850 | 0.72 | SMN1; SMN2 (0.42) | SMN1; SMN2TAAR1FAAHADRA2AADRA2B | |
| SCHEMBL5407676 | 0.71 | SMN1; SMN2 (0.49) | SMN1; SMN2TAAR1FAAH | |
| SCHEMBL13351520 | 0.71 | SMN1; SMN2 (0.49) | SMN1; SMN2TAAR1FAAH | |
| SCHEMBL29094266 | 0.71 | TAAR1 (0.74) | SMN1; SMN2TAAR1 | |
| SCHEMBL7540775 | 0.69 | SMN1; SMN2 (0.52) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153791-B2 | substituted pyrimidine compoundssuch as 4-amino-6-(3-chloro-4-fluoro-phenylamino)-pyrimidine-5-carbaldehyde O-methyl oxime, used for treating, preventing or ameliorating a chronic or acute protein kinase mediated diseasea, disorders or conditions | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-04-10 | — | — | US | claimed |
| US-8153791-B2 | substituted pyrimidine compoundssuch as 4-amino-6-(3-chloro-4-fluoro-phenylamino)-pyrimidine-5-carbaldehyde O-methyl oxime, used for treating, preventing or ameliorating a chronic or acute protein kinase mediated diseasea, disorders or conditions | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-04-10 | — | — | US | disclosed |